Results 31 to 40 of about 3,554 (229)
The Concise Guide to PHARMACOLOGY 2023/24: Catalytic receptors
British Journal of Pharmacology, Volume 180, Issue S2, Page S241-S288, October 2023., 2023 The Concise Guide to PHARMACOLOGY 2023/24 is the sixth in this series of biennial publications. The Concise Guide provides concise overviews, mostly in tabular format, of the key properties of approximately 1800 drug targets, and nearly 6000 interactions with about 3900 ligands.
Stephen P. H. Alexander +27 more
wiley +1 more source
Combined treatment of somatostatin analogues with pegvisomant in acromegaly [PDF]
, 2016 Treatment of acromegaly with monotherapy long-acting somatostatin analogues (LA-SSA) as primary treatment or after neurosurgery can only achieve complete normalization of insulin-like growth factor I (IGF-I) in roughly 40 % of patients.
Franck, S.E. (Sanne) +3 more
core +3 more sources
Magnetic resonance imaging as a predictor of therapeutic response to pasireotide in acromegaly
Clinical Endocrinology, Volume 99, Issue 4, Page 378-385, October 2023., 2023 Abstract Objective Hyperintensity signal in T2‐weighted magnetic resonance imaging (MRI) has been related to better therapeutic response during pasireotide treatment in acromegaly. The aim of the study was to evaluate T2 MRI signal intensity and its relation with pasireotide therapeutic effectiveness in real‐life clinical practice. Design, Patients and
Sabina Ruiz +23 more
wiley +1 more source
F1000Research, 2017 Background: Growth hormone (GH) is known to affect insulin and glucose metabolism. Blocking its effects in acromegalic patients improves diabetes and glucose metabolism.
Ada P. Lee +4 more
doaj +1 more source
Blockade of the growth hormone (GH) receptor unmasks rapid GH-releasing peptide-6-mediated tissue-specific insulin resistance [PDF]
, 2001 The roles of GH and its receptor (GHR) in metabolic control are not yet fully understood. We studied the roles of GH and the GHR using the GHR antagonist pegvisomant for metabolic control of healthy nonobese men in ...
Bidlingmaier, M. (Martin) +6 more
core +1 more source
Archives of Endocrinology and Metabolism, 2016 Objective To describe the safety and efficacy of pegvisomant therapy and the predictors of treatment response in acromegaly patients at a single tertiary reference center in Brazil.
Leandro Kasuki +7 more
doaj +1 more source
A male patient with acromegaly and breast cancer: treating acromegaly to control tumor progression [PDF]
, 2015 BACKGROUND: Acromegaly is a rare disease associated with an increased risk of developing cancer. CASE PRESENTATION: We report the case of a 72-year-old man who was diagnosed with acromegaly (IGF-1 770 ng/ml) and breast cancer.
Alberto Zambelli +7 more
core +1 more source
Bagcilar Medical Bulletin, 2022 McCune-Albright syndrome constitutes of fibrous dysplasia, café-au-lait macules, and various endocrinopathies such as thyroid, cortisol, prolactin and growth hormone hypersecretion.
Hande Peynirci, Onur Elbasan
doaj +1 more source
Resistance to drug treatment of acromegaly and ways to overcome it
Ожирение и метаболизм, 2021 Acromegaly is a severe disabling neuroendocrine disease caused by hypersecretion of growth hormone (GH) and insulin-like growth factor 1 (IGF-1). The problem of resistance to drug therapy in patients with acromegaly is quite common in clinical practice ...
O. O. Golounina +3 more
doaj +1 more source
Cost-effectiveness analysis of preoperative treatment of acromegaly with somatostatin analogue on surgical outcome [PDF]
, 2015 [Abstract] Context. There is no uniform standard of care for acromegaly. Due to the high costs involved, steps must be taken to ensure the cost-effective delivery of treatment. Objective.
Cordido, Fernando +7 more
core +2 more sources